Supernus Pharmaceuticals,Inc. (NASDAQ:SUPN) Files An 8-K Other Events
Item 8.01 Other Events.
On March27, 2019, Supernus Pharmaceuticals,Inc. (the “Company”) issued a press release announcing that the Company will issue a press release and host a conference call on March28, 2019, to discuss the topline results of its final Phase III study for SPN-812 in patients 12-17 years old (P304) for the treatment of attention deficit hyperactivity disorder (“ADHD”). A copy of this press release is furnished as Exhibit99.1 hereto and is incorporated herein by reference.
On March28, 2019, the Company issued a press release announcing topline results from its P304 study for the treatment of ADHD in patients 12-17 years old, which is the Company’s fourth clinical trial in the SPN-812 Phase III program. A copy of this press release is furnished as Exhibit99.2 hereto and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibit
The following document is furnished as an Exhibit to Item 8.01 hereof:
Exhibit99.1 — Press Release Dated March27, 2019.
Exhibit99.2 — Press Release Dated March28, 2019.
Exhibit99.3 — Presentation Slides.
SUPERNUS PHARMACEUTICALS INC Exhibit
EX-99.1 2 a19-7418_1ex99d1.htm EX-99.1 Exhibit 99.1 Supernus Hosts Conference Call to Present Topline Results of Final Phase III Study for SPN-812 in Adolescents with ADHD ROCKVILLE,…
To view the full exhibit click here
About Supernus Pharmaceuticals,Inc. (NASDAQ:SUPN)
Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR). It develops multiple product candidates in psychiatry for the treatment of Impulsive Aggression (IA) and attention deficit hyperactivity disorder (ADHD). Its psychiatry product candidates include SPN-810 (molindone hydrochloride) and SPN-812 (viloxazine hydrochloride). It is also developing SPN-810 as a treatment for IA in patients who have ADHD and SPN-812 for the treatment of ADHD. It is developing SPN-809 (viloxazine hydrochloride) for the treatment of depression. It markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States.
